^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VesiGel (mitomycin intravesicular)

    i
    Other names: UGN-102, mitomycin C mixed with TC-3 gel, MMC gel
    Associations

    News

    Trials
    Company:
    UroGen
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    UTOPIA: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=87, Recruiting, UroGen Pharma Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    VesiGel (mitomycin intravesicular)
    8ms
    UTOPIA: A Phase 3 Single-arm Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=87, Not yet recruiting, UroGen Pharma Ltd.
    New P3 trial
    |
    VesiGel (mitomycin intravesicular)
    12ms
    Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P3, N=8, Completed, UroGen Pharma Ltd. | Active, not recruiting --> Completed | Phase classification: P3b --> P3 | Trial completion date: May 2023 --> Feb 2023
    Trial completion • Phase classification • Trial completion date
    |
    VesiGel (mitomycin intravesicular)
    1year
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). (PubMed, J Urol)
    Primary, non-surgical chemoablation with UGN-102 for the management of LG IR NMIBC offers a potential therapeutic alternative to immediate TURBT monotherapy and warrants further investigation.
    P3 data • Journal
    |
    VesiGel (mitomycin intravesicular)